Abstract
A practicable six-step synthetic pathway has been developed to access a library of novel 3-[(N-cycloalkylbenzamido)methyl]-2-quinolones using Morita-Baylis-Hillman methodology. These compounds and their 3-[(N-cycloalkylamino)methyl]-2-quinolone precursors have been screened as potential HIV-1 integrase (IN) inhibitors. A concomitant survey of their activity against HIV-1 protease and reverse-transcriptase reveals selective inhibition of HIV-1 IN.
Keywords:
2-quinolones; Bioassay; HIV-1 integrase inhibitors; Morita_Baylis-Hillman; Synthesis.
Copyright © 2017 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Cell Survival / drug effects
-
Enzyme Activation / drug effects
-
HEK293 Cells
-
HIV Integrase / chemistry*
-
HIV Integrase / metabolism
-
HIV Integrase Inhibitors / chemical synthesis*
-
HIV Integrase Inhibitors / metabolism
-
HIV Integrase Inhibitors / pharmacology
-
HIV Reverse Transcriptase / antagonists & inhibitors
-
HIV Reverse Transcriptase / metabolism
-
HIV-1 / enzymology*
-
Humans
-
Quinolones / chemistry*
-
Quinolones / metabolism
-
Quinolones / pharmacology
-
Structure-Activity Relationship
Substances
-
HIV Integrase Inhibitors
-
Quinolones
-
HIV Integrase
-
reverse transcriptase, Human immunodeficiency virus 1
-
HIV Reverse Transcriptase